Molecular Partners AG

Equities

MOLN

CH0256379097

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 10:59:33 2024-04-25 am EDT			5-day change	1st Jan Change
3.34 ^CHF	+2.45%		-0.90%	-3.49%

Mar. 15	Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024
Mar. 15	Molecular Partners Swings to Loss in FY23; Revenue Down	MT

Molecular Partners AG : Molecular Partners Publishes Invitation to Annual General Meeting 2018

March 21, 2018 at 02:02 am EDT

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 21, 2018 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today published the invitation to the Annual General Meeting 2018.

The Annual General Meeting will be held on Wednesday, April 18, 2018, 2.00 pm CET (doors open at 1.30 pm), at the registered office of the company:
Molecular Partners AG, Wagistrasse 14, 5^th floor, 8952 Schlieren, Switzerland.

Link to the Invitation to the Annual General Meeting 2018 with the corresponding agenda items.

Link zur Einladung zur Generalversammlung 2018 mit den zugehörigen Traktandenpunkten.

Financial Calendar

http://investors.molecularpartners.com/financial-calendar-and-events/

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Dr. Patrick Amstutz, CEO
patrick.amstutz@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Andreas.Emmenegger, CFO
andreas.emmenegger@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Hirzel.Neef.Schmid.Counselors
rolf.schlaepfer@konsulenten.ch
Tel: +41 (0) 43 344 42 42

Susan A. Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
Tel: +1 212 966 3650

*DARPin® is a registered trademark owned by Molecular Partners AG

SOURCE: Molecular Partners AG

Latest news about Molecular Partners AG

Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024	Mar. 15
Molecular Partners Swings to Loss in FY23; Revenue Down	Mar. 15	MT
Molecular Partners AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
US Court Dismisses Putative Class Action Against Molecular Partners	Mar. 03	MT
Transcript : Molecular Partners AG Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM	Jan. 10
Molecular Partners Gears Up for 2024 Milestones, Including Data From Leukemia Treatment Trial	Jan. 08	MT
Molecular Partners, Orano Med Team Up to Develop Radio-DARPin Therapeutics Against Cancer	Jan. 08	MT
Molecular Partners AG and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies	Jan. 05	CI
Novocure Names Nicolas Leupin as Chief Medical Officer	Jan. 04	MT
ADRs Advance; Boqii Holding Ltd. Climbs 16.2%	Jan. 04	DJ
ADRs Hold Steady; TDCX Inc. Climbs 30.4%	Jan. 03	DJ
Molecular Partners Reports 'Encouraging' Initial Data From Phase 1/2a Trial of MP0533	Dec. 11	MT
Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting	Dec. 10	CI
JPMorgan Cuts Molecular Partners Price Target to $4.50 From $6.60, Maintains Neutral Rating	Dec. 05	MT
Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting	Nov. 03	CI
Molecular Partners Says Preliminary Data From MP0533's Phase 1/2a Trial Show 'Acceptable Safety Profile'	Nov. 02	MT
Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition	Nov. 02	CI
Molecular Partners AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Molecular Partners AG(SWX:MOLN) dropped from S&P Global BMI Index	23-09-18	CI
Transcript : Molecular Partners AG, H1 2023 Earnings Call, Aug 25, 2023	23-08-25
Molecular Partners' Chief Medical Officer to Step Down; Interim Successor Named	23-08-25	MT
Molecular Partners Turns to Loss in H1; Revenue Slides Down	23-08-24	MT
Molecular Partners AG Announces Executive Changes	23-08-24	CI
Molecular Partners AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Molecular Partners AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI

Chart Molecular Partners AG

Duration

Period

More charts

Company Profile

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q1 2024 Sales and Revenue Release - Interim Management Statement

More about the company

Income Statement Evolution

More financial data

Ratings for Molecular Partners AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.26 CHF

Average target price

9.35 CHF

Spread / Average Target

+186.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MOLECULAR PARTNERS AG	-3.49%	117M
VERTEX PHARMACEUTICALS INCORPORATED	-3.28%	104B
REGENERON PHARMACEUTICALS, INC.	-0.06%	97.42B
ARGENX SE	+1.31%	22.2B
BIONTECH SE	-18.25%	21.23B
GENMAB A/S	-10.74%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.17%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.60%	13.98B
SAREPTA THERAPEUTICS, INC.	+27.51%	11.66B

Bio Therapeutic Drugs